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OBJECTIVE — To determine whether dapagliﬂozin, which selectively inhibits renal glucose
reabsorption, lowers hyperglycemia in patients with type 2 diabetes that is poorly controlled
with high insulin doses plus oral antidiabetic agents (OADs).
RESEARCHDESIGNANDMETHODS — Thiswasarandomized,double-blind,three-
armparallel-group,placebo-controlled,26-centertrial(U.S.andCanada).Basedondatafroman
insulin dose-adjustment setting cohort (n  4), patients in the treatment cohort (n  71) were
randomly assigned 1:1:1 to placebo, 10 mg dapagliﬂozin, or 20 mg dapagliﬂozin, plus OAD(s)
and 50% of their daily insulin dose. The primary outcome was change from baseline in A1C at
week 12 (dapagliﬂozin vs. placebo, last observation carried forward [LOCF]).
RESULTS — At week 12 (LOCF), the 10- and 20-mg dapagliﬂozin groups demonstrated
0.70 and 0.78% mean differences in A1C change from baseline versus placebo. In both
dapagliﬂozingroups,65.2%ofpatientsachievedadecreasefrombaselineinA1C0.5%versus
15.8% in the placebo group. Mean changes from baseline in fasting plasma glucose (FPG) were
17.8, 2.4, and 9.6 mg/dl (placebo, 10 mg dapagliﬂozin, and 20 mg dapagliﬂozin, respec-
tively).Postprandialglucose(PPG)reductionswithdapagliﬂozinalsoshoweddosedependence.
Mean changes in total body weight were 1.9, 4.5, and 4.3 kg (placebo, 10 mg dapagliﬂo-
zin, and 20 mg dapagliﬂozin). Overall, adverse events were balanced across all groups, although
more genital infections occurred in the 20-mg dapagliﬂozin group than in the placebo group.
CONCLUSIONS — Inpatientsreceivinghighinsulindosesplusinsulinsensitizerswhohad
their baseline insulin reduced by 50%, dapagliﬂozin decreased A1C, produced better FPG and
PPG levels, and lowered weight more than placebo.
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T
reatment of hyperglycemia in pa-
tientswithtype2diabetesremainsa
challenge, particularly in those who
require insulin as the disease progresses
(1,2). Various combinations of insulin
withoralantidiabeticagents(OADs)have
been investigated (2–8). Often, these
combination therapies become less effec-
tive in controlling hyperglycemia over
time,particularlyasaresultofweightgain
and worsening insulin resistance as well
as progressive failure of insulin secretion.
Hypoglycemia, weight gain, and sub-
sequent increased insulin resistance are
signiﬁcant factors that limit optimal titra-
tion and effectiveness of insulin (2).
Weight gain with insulin therapy, used
alone or with OADs (7–9), is in part a
consequence of reducing glucosuria
(10,11). Among commonly used OADs,
thiazolidinediones (TZDs) and sulfonyl-
ureas intrinsically contribute to weight
gain, whereas metformin causes weight
lossanddipeptidylpeptidase-4inhibitors
areweightneutral.Overall,thereisaneed
for novel agents that can be safely admin-
istered to help achieve glycemic targets
without increasing the risks of weight
gain or hypoglycemia.
A novel approach to treating hyper-
glycemia targets receptors for renal glu-
cose reabsorption (12). Agents that
selectivelyblocksodium-glucosecotrans-
porter2(SGLT2),locatedintheproximal
tubuleofthekidney,inhibitglucosereab-
sorption and induce its elimination
through urinary excretion (13). Preclini-
cal models have shown that SGLT2
inhibition lowers blood glucose indepen-
dently of insulin (14–17). Dapagliﬂozin,
a highly selective inhibitor of SGLT2, has
demonstrated efﬁcacy, alone or in combi-
nation with metformin, in reducing hy-
perglycemia in patients with type 2
diabetes (18,19) but has not been tested
in patients requiring insulin. This study
wasdesignedtodeterminewhetherdapa-
gliﬂoziniseffectiveinloweringbloodglu-
cose in patients with type 2 diabetes who
have not responded adequately to insulin
combined with oral therapies that act
through insulin-dependent mechanisms.
RESEARCH DESIGN AND
METHODS— This randomized, sin-
gle- and double-blind, three-arm parallel-
group, placebo-controlled trial was
conducted in 26 study centers in the U.S.
and Canada. Institutional review boards or
independent ethics committees for each
center approved the protocol. All patients
provided written informed consent. The
trial consisted of a 10- to 21-day qualiﬁca-
tion period, 12-week treatment phase, and
4-week follow-up phase. Starting at day
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exerciseprogram,pursuanttoAmericanDi-
abetes Association or similar local guide-
lines, to be followed throughout the study.
Untilday1,patientsmaintainedtheirstable
dose of OADs and insulin.
We used an adaptive trial design with
two cohorts. The purpose of the ﬁrst co-
hort was to identify a reduced insulin
startingdoseunlikelytocausehypoglyce-
mia after addition of dapagliﬂozin. Four
patients received single-blind 20 mg
dapagliﬂozinafterhavingtheirdailyinsu-
lin dose decreased by 50%. If at least one
patient recorded a glucose value 100
mg/dl in this cohort, lesser dose reduc-
tions (i.e., 30 or 10%) would not be
tested, and the daily insulin dose reduc-
tion for patients in the larger second co-
hort would be set at 50%. This was the
case, and in the second treatment cohort,
patientswererandomlyassigned1:1:1on
day 1 to double-blind placebo, 10 mg
dapagliﬂozin, or 20 mg dapagliﬂozin
once daily, in addition to open-label ther-
apy with 50% of their usual daily insulin
dose and their OAD(s).
Patientsperformedself-monitoringof
blood glucose ﬁve times daily during the
3–5 days before clinic visits at weeks 1, 2,
4,6,8,10,and12.Nodosemodiﬁcations
of blinded study medication or OAD(s)
were allowed during the treatment phase.
In patients with or at risk of hypoglyce-
mia, insulin could be down-titrated for
self-monitored blood glucose levels 54
mg/dl or mean daily glucose 100 mg/dl
or when clinically necessary as deter-
mined by the investigator. Patients expe-
riencing major hypoglycemia were
discontinuedfromthestudy.Foranyfast-
ing plasma glucose (FPG) level 240
mg/dl at weeks 4 and 6, 220 mg/dl at
week 8, or 200 mg/dl at week 10, the
insulin dose could be increased after a re-
test. Patients lacking glycemic control de-
spite up-titration or whose modiﬁed
insulin dose exceeded baseline were dis-
continued from the study.
Menandwomenwithtype2diabetes,
aged 18–75 years, with BMI 45 kg/m
2
and A1C 7.5–10%, were enrolled be-
tween October 2006 and November
2007. Patients were receiving stable-dose
insulin sensitizer therapy (metformin
1,000 mg and/or pioglitazone 30 mg
or rosiglitazone 4 mg) for 6 weeks and
insulin therapy for 12 weeks before en-
rollment (insulin dose must have been
50 units of U100 daily and stable for
6 weeks). Laboratory criteria included
fasting C-peptide 0.8 ng/ml, serum cre-
atinine 1.5 mg/dl (men) or 1.4 mg/dl
(women), and a urine microalbumin-to-
creatinine ratio 300 mg/g or, if ex-
ceeded on spot check, a 24-h urine total
protein 3 g/24 h. Major exclusion crite-
ria were a history of type 1 diabetes, as-
partate transaminase and/or alanine
transaminase 2.5 times the upper limits
of normal, creatine kinase 3 times the
upper limits of normal, symptoms of se-
verely uncontrolled diabetes, a history of
severehypoglycemia,andunstablecondi-
tion or serious cardiovascular, renal, or
hepatic disease.
Trial outcomes (dapagliﬂozin vs.
placebo)
The primary efﬁcacy measure was
change from baseline in A1C at week 12
(last observation carried forward
[LOCF]). Secondary efﬁcacy measures
at week 12 (LOCF) included changes
from baseline in FPG and total daily
dose of insulin (TDDI), the proportion
of patients achieving a decrease in A1C
0.5% from baseline, and the propor-
tion of patients achieving A1C 7%.
Tertiary end points included changes
from baseline in total body weight and
in postprandial glucose (PPG) mea-
sured by an oral glucose tolerance test.
Safety outcomes were assessed by treat-
ment-emergent adverse events, vital
signs,andlaboratorymeasurements,in-
cluding 24-h urine collections for vol-
ume and electrolytes.
Statistical analysis
For the treatment cohort, the sample size
target of 22 patients per treatment group
was chosen to allow for the calculation of
95% CI for the primary end point with a
half-width of 0.42% for each treatment
group, assuming a 1% SD; the half-width
Figure 1—Patient disposition.
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treatment changes was estimated to be
0.59%. The primary efﬁcacy dataset con-
sisted of all randomly assigned patients
who took 1 dose of double-blind study
medication. Analyses of efﬁcacy variables
(except change from baseline in insulin
dose) excluded data after insulin up-
titration. Analyses for change from base-
line in A1C, FPG, insulin dose, and total
bodyweightatweek12(LOCF)wereper-
formed using an ANCOVA model with
treatment group as effect and baseline
valueasacovariate.Nostatisticalhypoth-
esis testing was planned for this study de-
signed for exploratory analysis.
RESULTS
Patient population
Of 163 patients screened for the treat-
ment cohort, 71 were randomly assigned
(Fig. 1). Demographic and baseline char-
acteristics are reported in Table 1.
Efﬁcacy outcomes
Figure2showsA1C,FPG,andchangefrom
baseline in body weight over time. In the
10- and 20-mg dapagliﬂozin groups, A1C
decreased from baseline to week 12
(LOCF), resulting in differences in mean
changes versus placebo of 0.70 and
0.78% (Table 2). At week 12 (LOCF),
65.2% of patients in both dapagliﬂozin
groups achieved a 0.5% decrease from
baseline A1C versus 15.8% in the placebo
group. Five patients (one each in the dapa-
gliﬂozin 20-mg and placebo groups, and
three in the dapagliﬂozin 10-mg group)
showed a therapeutic response deﬁned as
A1C 7%. At week 12 (LOCF), mean
changes in total body weight were 1.9 kg
(placebo), 4.5 kg (10 mg dapagliﬂozin),
and 4.3 kg (20 mg dapagliﬂozin).
The effect of dapagliﬂozin on FPG
was dose dependent. PPG, measured at
120 min by an oral glucose tolerance test,
also showed dose-response characteris-
tics. There was no appreciable change
from baseline in TDDI. Four patients in
the placebo arm required insulin up-
titration, compared with one in the dapa-
gliﬂozin 10-mg arm and three in the
dapagliﬂozin 20-mg arm.
Vital signs and laboratory outcomes
The placebo group experienced a slight
increase in standing blood pressure at
week 12, whereas both dapagliﬂozin
groups demonstrated mean improve-
ments in standing systolic and diastolic
blood pressure (7.2 systolic/–1.2 dia-
stolic mmHg [10 mg dapagliﬂozin] and
6.1 systolic/–3.9 diastolic mmHg [20
mg dapagliﬂozin]). In the 20-mg dapagli-
ﬂozin group, supine blood pressure de-
creased (mean change of 5.5 mmHg
systolic/–5.8 mmHg diastolic), whereas
there was little or no change in the 10-mg
group (supplementary Table 1, available
in the online appendix).
Mean changes from baseline in uri-
nary glucose excretion at week 12 were
1.5 g/24 h (placebo), 83.5 g/24 h (10
mg dapagliﬂozin), and 85.2 g/24 h (20
mg dapagliﬂozin). Mean 24-h urine out-
put increased from 1,870 to 2,125 ml
(placebo),from1,921to2,286ml(10mg
dapagliﬂozin), and from 1,809 to 2,253
ml(20mgdapagliﬂozin).Comparedwith
baseline, Modiﬁcation of Diet in Renal
Disease–estimated glomerular ﬁltration
ratesattheendoftreatmentwerenormal,
with minor changes of 0.58, 0.84,
and 1.45 ml/min per 1.73 m
2 in the re-
spective placebo and 10- and 20-mg
dapagliﬂozin groups. Generally, there
Table 1—Demographic and baseline characteristics of randomly assigned patients in the treatment cohort
Placebo  insulin
10 mg dapagliﬂozin 
insulin
20 mg dapagliﬂozin 
insulin
n 23 24 24
Age (years) 58.4  6.5 55.7  9.2 56.1  10.6
Sex
Male 16 (69.6) 13 (54.2) 13 (54.2)
Female 7 (30.4) 11 (45.8) 11 (45.8)
Race
White 22 (95.7) 22 (91.7) 23 (95.8)
Black/African American 0 1 (4.2) 1 (4.2)
Asian 0 1 (4.2) 0
Other 1 (4.3) 0 0
Ethnicity*
Hispanic/Latino 5 (21.7) 3 (12.5) 2 (8.3)
Non-Hispanic/Latino 12 (52.2) 14 (58.3) 16 (66.7)
Not reported 6 (26.1) 7 (29.2) 6 (25.0)
Weight (kg) 101.8  16.5 103.4  10.2 101.2  15.3
BMI (kg/m
2) 34.8  4.6 35.5  3.6 36.2  4.6
Duration of type 2 diabetes (years) 13.8  7.3 11.8  5.8 11.3  5.6
Background antihyperglycemic medication
Metformin  insulin 18 (78.3) 19 (79.2) 16 (66.7)
Metformin  insulin  TZD 4 (17.4) 2 (8.3) 6 (25.0)
TZD  insulin 1 (4.3) 3 (12.5) 2 (8.3)
Total daily insulin dose† 90.0 (70.0–136.0) 93.0 (67.5–136.0) 84.5 (58.0–135.5)
A1C (%) 8.4  0.9 8.4  0.7 8.5  0.9
FPG (mg/dl) 165.9  51.5 156.0  39.0 161.6  55.0
Data are means  SD, n (%), or median (interquartile range). *Ethnicity data were collected for sites in the U.S. only. †Before 50% insulin dose reduction on day
1 of double-blind period.
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lineinkeylaboratoryparameters.Median
change from baseline in serum uric acid
was 0.30 mg/dl in both dapagliﬂozin
groups.Therewerenomarkedabnormal-
ities for serum Na
 and liver function
tests. Median increases from baseline in
serum hematocrit at week 12 were 2.5
and 3.05% in the 10- and 20-mg dapagli-
ﬂozin groups, respectively.
Safety and adverse events
Adverse events were balanced across all
groups (Table 3). Three patients who re-
ceived placebo, seven who received 10
mgdapagliﬂozin,andsixwhoreceived20
mg dapagliﬂozin experienced episodes of
hypoglycemia. Of these, one patient who
received placebo experienced major hy-
poglycemia. There were no deaths. Two
patients,oneintheplaceboandoneinthe
20-mgdapagliﬂozingroup,experienceda
seriousadverseevent.Onepatientineach
treatment arm experienced an adverse
event that led to discontinuation.
Six patients experienced genital tract
infections during the double-blind pe-
riod;ﬁveofthesereceived20mgdapagli-
ﬂozin. One patient in the 20-mg
dapagliﬂozin group reported a urinary
tract infection. Events of pollakiuria were
reported across all treatment groups, in-
cludingtheplacebogroup.Onepatientin
each dapagliﬂozin arm reported polyuria.
One case of microalbuminuria in the
20-mg dapagliﬂozin arm resulted in
discontinuation.
One event of renal failure occurred
during treatment with 10 mg dapagliﬂo-
zin. The patient was being chronically
treated with multiple antihypertensive
agents, including enalapril, carvedilol,
andfurosemide.Elevendaysafterstarting
studymedication,thepatientwasdiscon-
tinued from the study because of dehy-
dration and prerenal azotemia.
Furosemide and enalapril therapy were
withheld, and the prerenal azotemia re-
solved with oral rehydration.
CONCLUSIONS — Disease progres-
sion in type 2 diabetes is frequently ac-
companied by a cycle of deteriorating
glycemic control due to declining -cell
function. Therapies that depend on insu-
lin supplementation or secretion entail
theriskofhypoglycemia,weightgain,de-
creased insulin sensitivity, and eventual
loss of effectiveness. This frustrating clin-
ical setting is exempliﬁed most dramati-
cally by patients with late-stage type 2
diabetes who require escalating insulin
Figure 2—Mean A1C (A), mean FPG (B), and mean change from baseline in total body weight
(C) over time. Data are for randomly assigned patients who took at least one dose of the double-
blind study medication. Shown are mean values based on LOCF, excluding data after up-titration
of insulin. Error bars represent 95% CIs. DAPA, dapagliﬂozin; INS, insulin; PLA, placebo.
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formin and/or TZDs to maintain glycemic
control.Ultimately,25%ofpatientsare
treated with insulin-based regimens, of-
ten in combination with OADs (6). A
novelstrategyforcontrollingglycemiain-
dependently of insulin involves limiting
glucose reabsorption in the proximal
tubule of the kidney, where glucose is
reabsorbedviaSGLT2receptors.Dapagli-
ﬂozin selectively inhibits SGLT2, thereby
limiting glucose reabsorption.
Patients recruited for this study had
inadequate glycemic control despite ag-
gressive regimens of insulin plus OADs.
After reducing the insulin dose by 50%,
patients in the placebo arm experienced
weight loss, little change in A1C, and a
mean 17.8 mg/dl increase in FPG, an out-
come that probably reﬂects the relatively
severe insulin resistance in these patients
and perhaps improved compliance with
diet and lifestyle as a result of study par-
ticipation. Treatment with dapagliﬂozin,
with its insulin-independent mechanism
of action, was associated with additional
weightlossof2.5kgandwithimprove-
mentsinglycemiccontrolcomparedwith
placebo.Althoughthetotalnumberofhy-
poglycemic events reported was greater
with dapagliﬂozin than with placebo,
there were no major hypoglycemia epi-
sodes with dapagliﬂozin. The effect of
dapagliﬂozin in this insulin-treated pop-
ulation was similar to that observed in
treatment-naive diabetic patients (19).
Improvements in glycemic outcome
measures were dose dependent, as was
the potential safety signal of genital tract
infections, more frequently seen in the
20-mg dapagliﬂozin dose arm. However,
the main pharmacodynamic measure,
24-h urinary glucose, increased by 85
g/day at week 12 in both the 10-mg and
20-mg dapagliﬂozin groups. A plausible
explanation is that 20 mg dapagliﬂozin
may have caused greater glucosuria ear-
lier in the study, as has been seen in other
settings (18–20), but that the resulting
greater declines in glycemia in the 20-mg
dose group led to a lower ﬁltered load of
glucose at the kidney, such that by week
12, the point at which glucosuria was
measured, the amount of glucose in the
urine had equalized between the dapagli-
ﬂozin dose groups.
Reductions in standing blood pres-
sure in both dapagliﬂozin groups and in
supinebloodpressureinthedapagliﬂozin
20-mg group are noteworthy. The de-
crease in blood pressure and slight in-
crease in hematocrit are effects consistent
with the glucose-induced osmotic diure-
sis caused by SGLT2 inhibition. A dra-
matic presentation of this effect was seen
in the 10-mg dose arm in an event of de-
hydration and prerenal azotemia in a vol-
ume-sensitive patient. Otherwise, there
werenofurtherreportsofdizzinessorde-
hydrationassociatedwithdapagliﬂozinin
this study. The diuretic property of dapa-
gliﬂozin warrants further evaluation.
Conclusions that can be drawn from
this study are limited by its size and rela-
tivelyshortduration.Nevertheless,thesere-
Table 2—Baseline, with treatment, and change from baseline in efﬁcacy parameters for randomly assigned patients in the treatment cohort
n Baseline*
Week 12
(LOCF)*
Change from baseline and differences
in change vs. placebo  insulin*†
A1C (%)
Placebo  insulin 19‡ 8.3  0.8 8.5  0.8 0.09 (0.2 to 0.4)
10 mg dapagliﬂozin insulin 23‡ 8.4  0.7 7.8  0.7 0.61 (0.9 to 0.4)
Difference in change vs. placebo  insulin 0.70 (1.1 to 0.3)
20 mg dapagliﬂozin insulin 23‡ 8.5  0.9 7.8  0.6 0.69 (0.9 to 0.4)
Difference in change vs. placebo  insulin 0.78 (1.2 to 0.4)
FPG (mg/dl)
Placebo  insulin 22‡ 166.8  52.6 180.8  56.9 17.8 (1.4 to 34.2)
10 mg dapagliﬂozin  insulin 23‡ 155.7  39.8 160.5  38.7 2.4 (13.6 to 18.3)
Difference in change vs. placebo  insulin 15.4 (38.4 to 7.5)
20 mg dapagliﬂozin  insulin 23‡ 157.9  53.0 149.4  32.0 9.6 (25.6 to 6.3)
Difference in change vs. placebo  insulin 27.4 (50.3 to 4.6)
Body weight (kg)
Placebo  insulin 22‡ 101.3  16.7 99.4  16.7 1.9 (2.9 to 0.9)
10 mg dapagliﬂozin  insulin 23‡ 102.8  9.9 98.2  9.4 4.5 (5.5 to 3.5)
Difference in change vs. placebo  insulin 2.6 (4.0 to 1.2)
20 mg dapagliﬂozin  insulin 23‡ 102.1  15.0 97.8  14.1 4.3 (5.3 to 3.3)
Difference in change vs. placebo  insulin 2.4 (3.8 to 1.0)
TDDI (units)
Placebo  insulin 22‡ 54.1  27.3 55.7  26.5 1.7 (3.8 to 7.2)
10 mg dapagliﬂozin  insulin 24‡ 52.4  24.4 51.3  20.1 1.4 (6.6 to 3.9)
Difference in change vs. placebo  insulin 3.1 (10.7 to 4.6)
20 mg dapagliﬂozin  insulin 24‡ 54.5  36.3 53.5  32.1 0.8 (6.1 to 4.5)
Difference in change vs. placebo  insulin 2.5 (10.2 to 5.1)
PPG (mg/dl)
Placebo  insulin 15‡ 312.6  82.2 331.3  46.8 18.7 (13.5 to 50.9)
10 mg dapagliﬂozin  insulin 19‡ 320.2  51.4 286.0  55.1 34.3 (67.5 to 1.1)
20 mg dapagliﬂozin  insulin 18‡ 314.5  71.8 272.6  51.2 41.9 (74.8 to 8.9)
Data are means  SD or mean (95% CI). n  71. *Excludes data after insulin up-titration, except for TDDI. †Adjusted change from baseline based on an ANCOVA
model with treatment group as an effect and baseline value as a covariate. ‡Number of subjects with a nonmissing baseline and a week 12 LOCF value.
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SGLT2 inhibition can improve glycemic
controlandweightinpatientswithdiabetes
that is poorly controlled with high insulin
doses and oral insulin sensitizer therapy,
despitea50%insulindosereduction.These
results further suggest the hypothesis that
this therapeutic approach may lend itself to
reducing the weight gain that otherwise
might occur when insulin therapy is inten-
siﬁed in this population.
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Nausea 1 (4.3) 1 (4.2) 3 (12.5)
Pollakiuria 4 (17.4) 2 (8.3) 3 (12.5)
Vomiting 3 (12.5)
Vulvovaginal mycotic infection 3 (12.5)
Anxiety 2 (8.3)
Back pain 2 (8.7) 3 (12.5) 2 (8.3)
Dry mouth 2 (8.3)
Nasopharyngitis 2 (8.7) 2 (8.3) 2 (8.3)
Edema, peripheral 2 (8.3)
Abdominal pain, upper 2 (8.7) 1 (4.2)
Fatigue 2 (8.3) 1 (4.2)
Inﬂuenza 2 (8.7) 1 (4.2) 1 (4.2)
Pain in extremity 1 (4.3) 2 (8.3) 1 (4.2)
Thirst 1 (4.3) 2 (8.3) 1 (4.2)
Upper respiratory tract infection 2 (8.7) 2 (8.3) 1 (4.2)
Headache 2 (8.7) 3 (12.5)
Pharyngolaryngeal pain 2 (8.3)
Procedural pain 2 (8.7)
Adverse events of special interest
Urinary tract infection 1 (4.2)
Genital tract infection (total patients with an event) 1 (4.3) 5 (20.8)
Vulvovaginal mycotic infection 3 (12.5)
Balanitis candida 1 (4.2)
Vaginal candidiasis 1 (4.2)
Genital infection, fungal 1 (4.3)
Events of hypoglycemia
Total patients with hypoglycemia 3 (13.0) 7 (29.2) 6 (25.0)
Major episode of hypoglycemia# 1 (4.3)
Discontinuation due to lack of glycemic control
Overall 2 (8.7) 1 (4.2)
Before up-titration of insulin 1 (4.3)
On or after day of up-titration of insulin 1 (4.3) 1 (4.2)
Data are n (%). *Events of hypoglycemia were evaluated separately from adverse events. †Loss of consciousness. ‡Noncardiac chest pain. §Blood creatine
phosphokinaseincreased.Renalfailure.Otheradverseeventsreportedwhenpatientwas“discontinued”includedincreasedbloodcreatinine,increasedbloodurea,
dehydration, and dizziness. ¶Microalbuminuria. #Major hypoglycemic episode deﬁned as 1) plasma blood glucose value 54 mg/dl, 2) at least one of the following
symptoms: confusion/disorientation, abnormal behavior, or unconsciousness, and 3) external treatment provided.
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